{
  "source": "PA-Notification-Talzenna.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1266-7\nProgram Prior Authorization/Notification\nMedication Talzenna® (talazoparib)\nP&T Approval Date 12/2018, 12/2019, 12/2020, 12/2021, 12/2022, 8/2023, 8/2024\nEffective Date 11/1/2024\n1. Background:\nTalzenna (talazoparib) is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated as a single\nagent for the treatment of adult patients with deleterious or suspected deleterious germline\nBRCA mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative locally\nadvanced or metastatic breast cancer. Appropriate patients for therapy are selected based on an\nFDA-approved companion diagnostic for Talzenna.1 Talzenna is also indicated in combination\nwith Xtandi (enzalutamide) for the treatment of adult patients with homologous recombination\nrepair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC). The\nNational Comprehensive Cancer Network (NCCN) also supports use of Talzenna in any\nlocalized or metastatic breast cancer subtype associated with a germline BRCA1 or BRCA2\nmutation.\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age of\n19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the\nnotification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Talzenna will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Breast Cancer\n1. Initial Authorization\na. Talzenna will be approved based on all of the following criteria:\n(1) Diagnosis of breast cancer\n-AND-\n© 2024 UnitedHealthcare Services, Inc.\n1\n(2) Disease is o",
    "east Cancer\n1. Initial Authorization\na. Talzenna will be approved based on all of the following criteria:\n(1) Diagnosis of breast cancer\n-AND-\n© 2024 UnitedHealthcare Services, Inc.\n1\n(2) Disease is one of the following:\n(a) Locally advanced\n(b) Metastatic\n-AND-\n(3) Presence of a germline BRCA-mutation\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Talzenna will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Talzenna\ntherapy\nAuthorization will be issued for 12 months.\nC. Prostate Cancer\n1. Initial Authorization\na. Talzenna will be approved based on all of the following criteria:\n(1) Diagnosis of metastatic castration-resistant prostate cancer\n-AND-\n(2) Presence of homologous recombination repair (HRR) gene mutations\n-AND-\n(3) Used in combination with Xtandi (enzalutamide)\n-AND-\n(4) One of the following:\n(a) Used in combination with a gonadotropin-releasing hormone (GnRH)\nanalog [e.g., Lupron (leuprolide), Zoladex (goserelin), Trelstar (triptorelin),\nVantas (histrelin), Firmagon (degarelix)]\n-OR-\n(b) Patient has had bilateral orchiectomy\n© 2024 UnitedHealthcare Services, Inc.\n2\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Talzenna will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Talzenna\ntherapy\nAuthorization will be issued for 12 months.\nD. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a\nCategory of Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealt",
    "ic\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class\n• Supply limits may be in place.\n• Step therapy may be in place.\n4. References:\n1. Talzenna [package insert]. New York, NY: Pfizer Labs, Feb 2024.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nhttp://www.nccn.org/professionals/drug_compendium/content/contents.asp. Accessed July 2,\n2024..\nProgram Prior Authorization/Notification – Talzenna (talazoparib)\nChange Control\n12/2018 New program.\n12/2019 Annual review. Added general NCCN recommendations for use\ncriteria. Updated background and references.\n12/2020 Annual review. Added reference to step therapy policy. Updated\nreferences.\n12/2021 Annual review. Updated clinical criteria based on NCCN\nrecommendations. Updated references.\n12/2022 Annual review. Added stated mandate and updated references.\n© 2024 UnitedHealthcare Services, Inc.\n3\n8/2023 Added criteria for HRR gene-mutated mCRPC per label. Updated\nbackground and references.\n8/2024 Annual review. Updated references.\n© 2024 UnitedHealthcare Services, Inc.\n4"
  ]
}